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SUMMARY 
Type 2 diabetes mellitus is associated with higher fracture risk. The present study investigated the 
beneficial role of sitagliptin on bone strength and bone composition in a mouse model of type 2 diabetes. 
Sitagliptin significantly increased bone strength by improving compromised bone composition.  
 
ABSTRACT 
Purpose/Introduction: Type 2 diabetes mellitus (T2DM) is recognized as a significant risk factor for 
fragility of bone. Among the newer anti-diabetic agents, dipeptidyl peptidase-4 inhibitors (DPP4i) have 
been reported to decrease the occurrence of bone fractures although the reason is unclear. The main 
aim of this study was to evaluate the impact of sitagliptin treatment on tissue bone strength and 
compositional parameters in the high fat fed mouse model.  
Methods: Male NIH swiss mice were allowed free access to high fat diet (HFD) for 150 days to induce 
chronic hyperglycemia and insulin resistance. Sitagliptin was administered once daily for 3 weeks. High 
fat fed mice administered with saline were used as controls. Bone strength was assessed at the organ 
and tissue level by 3-point bending and nanoindentation, respectively. Bone microarchitecture was 
investigated by microcomputed tomography and bone composition was evaluated by Fourier transform 
infrared imaging and quantitative backscattered electron imaging.  
Results: Administration of sitagliptin increased non-fasting insulin, improved glucose tolerance and 
increased insulin sensitivity. This was associated with clear ameliorations in bone strength at the organ 
and tissue level. No changes in trabecular or cortical microarchitectures were observed. On the other 
hand, higher values of Camean, Caturn, collagen maturity, mineral/matrix ratio, mineral maturity and crystal 
size index were evidenced after sitagliptin treatment. Correlation analysis significantly linked the 
modifications of bone strength to changes in bone compositional parameters.  
Conclusions: These results bring new light on the mode of action of sitagliptin on bone physiology and 
demonstrate a benefit of DPP4i.  
 
Keywords: sitagliptin, bone fragility, bone composition, type 2 diabetes  
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1. INTRODUCTION 
Type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), are associated with increased 
bone fragility fractures [1]. Whilst bone mineral density measurements may validate this detrimental 
bone effect in T1DM, this is not the case in T2DM, even after body mass index normalization [2, 3]. 
Although bone strength and fracture risk are assessed by measuring bone mineral density, the 
mechanical properties of bone are in fact determined not only by bone mass, but also by (1) the rate of 
bone turnover, (2) microdamage accumulation, (3) geometry/architecture of the bone, and (4) bone 
composition [4]. Alterations of bone turnover, microdamage accumulation and microarchitecture of bone 
have been studied and documented previously in T2DM [5-8]. However, although recent evidences 
pointed out to possible modifications of bone composition [9], data are scarce about which of these 
properties, i.e. post-translational collagen modifications, mineral density, mineral maturity, 
hydroxyapatite crystal size, ionic substitutions, etc…, are altered in T2DM.  
Furthermore, little is known about the impact of clinically available antidiabetic drugs on bone 
composition and should be investigated in order to understand better how these molecules may affect 
skeletal strength. Among the newer anti-diabetic agents, dipeptidyl peptidase-4 inhibitors (DPP4i) are 
administered orally and exhibit HbA1c lowering effects ranged between 0.6-1.4% [10]. DPP4 has a wide 
variety of substrates, which have important roles in metabolism, inflammation, cell migration and 
differentiation. One of the important groups is represented by glucagon-like peptide-1 and -2 (GLP-1 
and GLP-2, respectively), and glucose-dependent insulinotropic polypeptide (GIP). As such, the use of 
DPP4i prolongs action of these molecules by increasing their biological half-lives in the circulation.  
Previous human studies pointed to beneficial or neutral effects of DPP4i in reducing bone fractures [11-
18]. However, these studies were associated with several limitations that may hamper interpretation. 
Examination of skeletal response to DPP4i in preclinical diabetic animal models revealed positive effects 
in resisting bone fracture, despite the absence or only modest ameliorations in bone mineral density 
and/or trabecular and cortical bone microarchitectures [19-23], suggesting that the mechanisms behind 
better bone strength rely probably elsewhere than changes in bone mass or microarchitecture. With 
respect to the observed beneficial actions of GLP-1 and GIP on bone matrix at the tissue level [24, 25], 
a possible explanation could lie in amelioration of bone compositional parameters rather than bone 
microstructure.  Therefore, the aim of the present study was to evaluate whether the DPP4i, sitagliptin, 
improves skeletal health in the diabetic high fat fed mice. As such, we investigated bone strength at both 
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the organ and tissue levels, as well as trabecular and cortical bone microarchitectures and bone 
compositional parameters in the NIH Swiss mice.  
 
2. MATERIAL AND METHODS 
2.1 Animals 
All procedures were conducted according to UK Home Office Regulations (UK Animals Scientific 
Procedures Act 1986). Animal study is reported in compliance with the ARRIVE guidelines. Male NIH 
Swiss mice (NIH/OlaHsd) were obtained from Envigo Ltd (Blackthorn, UK) at 8 weeks of age. Animals 
were individually housed in an air-conditioned room at 22 ± 2°C with a 12-hour light/dark cycle, and were 
provided with tap water and high fat diet (HFD, 45% fat, 20% protein, 35% carbohydrate for a total of 
26.2 kJ/g; Special Diet Service, Essex, UK) ad libitum for 150 days prior to the start of the study. At the 
end of the 150 days period, all mice displayed fasted blood glucose level > 14 mmol/l and higher body 
weight (58 ± 5 vs 47 ± 7 g, p<0.05) than age-matched control mice on normal laboratory chow. HFD 
mice were divided in two groups (n=8/group) that received once daily orally either saline (0.9% NaCl – 
HFD+saline) or sitagliptin phosphate monohydrate (50 mg/kg bw; ApexBio Technology, Houston, TX, 
USA; >97% purity – HFD+Sitagliptin) for 3 weeks at the same time of day (9 am). No adverse effects 
were observed following drug treatment. Eight control mice fed a normal laboratory chow (10% fat, 30% 
protein and 60% carbohydrate for a total of 13 kJ/g; Trouw Nutrition, Northwich, UK) and receiving once 
daily orally saline were used as controls.  
Energy intake, body weight, plasma insulin, glucose tolerance (18 mmol/kg bw, ip, 18h fast) and insulin 
sensitivity (25 U/kg bw, ip) were assessed. Homeostatic model assessment of insulin resistance 
(HOMA-IR) and homeostatic model assessment of β-cell function (HOMA-β) were carried out using the 
following calculations: HOMA-IR = (fasting glucose x fasting insulin)/22.5, and HOMA-β = (20 x fasting 
insulin)/(fasting glucose – 3.5).  
Bone mineral density (BMD, g/cm2) and fat mass were measured with a Lunar PIXImus scanner (Inside 
Outside Sales, Wisconsin, U.S.A.). At necropsy, femurs and tibias were cleaned of soft tissues and 
stored in 70% ethanol at 4°C until used.  
 
2.2. MicroCT 
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MicroCT analyses were performed on tibias with a Skyscan 1172 microtomograph (Bruker MicroCT, 
Kontich, Belgium) operated at 70 kV, 100 µA, 340-ms integration time. The isotropic pixel size was fixed 
at 4 µm, the rotation step at 0.25° and exposure was done with a 0.5-mm aluminum filter. Each 3D 
reconstruction image dataset was binarized using global thresholding. Trabecular volume of interest 
(VOI) was located 0.5 mm below the growth plate and extended on 2-mm. Cortical volume of interest 
extended on 1-mm centered at the midshaft tibia. All histomorphometrical parameters were determined 
according to guidelines and nomenclature proposed by the American Society for Bone and Mineral 
Research [26].    
 
2.3. Bone histomorphometry 
After microCT, tibias were embedded, undecalcified in methylmethacrylate at 4°C to preserve enzyme 
activities. Sagittal sections (7-µm thickness) were performed on a heavy-duty microtome equipped with 
a 50° tungsten carbide knife. Four non-serial sections were stained with toluidine blue for the 
measurement of the number of osteoblasts and adipocytes. Four additional sections were stained for 
the osteoclastic tartrate resistant acid phosphatase (TRAcP). Four non-consecutive sections were 
stained with Goldner trichrome to assess the extent of osteoid formation. Histomorphometrical 
parameters were determined in the proximal tibia metaphysis. Standard bone histomorphometrical 
nomenclatures, symbol and units were used as described in the report of the American Society for Bone 
and Mineral Research [27]. 
 
2.4. Bone strength assessment 
Three-point bending experiments were performed on femurs after rehydrating bones at 4°C for 24 h. 
Femurs were loaded to failure in 3-point bending at 1 mm/min using an Instron 5942 (Instron, Elancourt, 
France). The lower span length was set to 10 mm. Femurs were oriented so the anterior quadrant was 
facing down and subjected to tensile loads. Load and displacement were digitally recorded at a sampling 
rate of 100 Hz and measured using a 500 N load cell (Instron). The load-displacement curve was 
computed with the Bluehill 3 software (Instron) and the maximum load, yield load (0.2% offset method), 
stiffness, post-yield displacement and work to failure were computerized. After three-point bending 
experiments, femurs were embedded undecalcified in polymethylmethacrylate (pMMA) at 4°C and 
cross-sections were made at the midshaft using a diamond saw (Accutom, Struers, Champigny sur 
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Marne, France). Blocks were sectioned with heavy-duty microtome equipped with a 50° tungsten 
carbide knife for FTIRI analyses. Samples were then polished to a 1-µm finish with diamond particles 
(Struers, France) before nanoindentation. Samples were subjected to rehydration in saline for 24 h. 
Twelve indentations, at distance from canals, osteocyte lacunae and/or microcracks were randomly 
positioned in cortical bone with a NHT-TTX system (Anton Paar, Les Ulis, France). Indentation depth 
was fixed at 900 nm with loading/unloading speed set at 40 mN/min. At maximum load, a holding period 
of 15 seconds was applied to avoid creeping of the bone material. The following material properties at 
the tissue-level, maximum load (Force max), indentation modulus (EIT), indentation hardness (HIT) and 
work of indentation (WI), corresponding to the area under the indentation curve, were determined 
according to Oliver and Pharr [28].  
Although local mineral content influences greatly the measured parameters in nanoindentation, we did 
not adjust nanoindentation parameters for local mineral content because (1) the range of Ca 
concentration values measured by qBEI is rather narrow, making a correlation analysis difficult and 
uncertain, (2) there are some inherent variations in apparent calcium levels due to the counting statistics 
accompanying backscattered electron signal, (3) there can be variations of modulus at given mineral 
content due to mechanical anisotropy of the mineralized collagen matrix, (4) the only apparent formula 
to adjust for mineral content is dependent on aspect ratio of the mineral particles [29]. Furthermore, 
nanoindentation was performed before qBEI measurements and specimen were repolished with silicon 
carbide paper (P4000) and diamond suspension on polishing clothes before being examined under the 
scanning electron microscope. As such although the amount of matter removed is negligible (~6 μm), 
we cannot obtain a perfect match between qBEI and nanoindentation locations.  
 
2.5. Fourier-transform infrared imaging (FTIRI) 
Cross-sectional sections (4 µm) of the midshaft femur were sandwiched between barium fluoride optical 
windows. FTIRI was performed with a vertex 70 spectrometer (Bruker, Ettlingen, Germany) interfaced 
with a Hyperion 3000 microscope and a focal plane array detector (64 x 64 pixels) covering a field of 
view of 180 x 180 µm. Nine consecutive field-of-view were stitched together to allow sufficient bone to 
be analyzed.  Sections were scanned with a spectral resolution of 8 cm-1 (spectral region 900-2000 cm-
1). Each spectrum was corrected for Mie scattering with the RMieS-EMSC_v5 algorithm (kind gift of Prof 
Peter Gardner, University of Manchester, UK) prior to be subjected to pMMA substraction. Evaluation 
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of spectral images was done with a lab-made routine script in Matlab R2016b (The Mathworks, Natick, 
MA). FTIR bone parameters [30] calculated were: (1) mineral/matrix ratio (area of 1,3 phosphate/area 
amide1); (2) acid phosphate content (intensity ratio 1127cm-1/1096 cm-1); (3) mineral maturity (intensity 
ratio 1030 cm-1/1020 cm-1), reflecting crystal size and perfection; and (4) collagen maturity (intensity 
ratio 1660 cm-1/1690 cm-1). The crystal size index was introduced based on intensity ratio 1075 cm-
1/1055 cm-1. The 1075 cm-1 subband has been shown to be positively and linearly correlated with crystal 
size in 002, 211, 200 and 202 directions determined by X-ray diffraction, whilst the 1055 cm-1 subband 
remains constant during crystal growth [31]. The carbonate/phosphate ratio (intensity 3 carbonate 
located at ~1415 cm-1/1030 cm-1) was computed after subtracting the organic matrix spectrum [32]. 
Histogram distribution for each parameter were fitted with a gaussian model and considered normally 
distributed if the R2 coefficient was > 0.95. In the present study, no histogram distribution deviated from 
normal distribution. For each of the compositional parameters, the mean and full width at half maximum 
of the pixel distribution (excluding the zero background values) were computed and represented as 
mean and heterogeneity.  
 
2.6. Quantitative backscattered electron imaging (qBEI) 
Analyses were performed on the same blocks as nanoindentation or used for FTIRI sections. Blocks 
were repolished to remove indentation marks at the surface of bone specimen. On average, this 
polishing procedure removed 6 µm of material. Blocks were carbon-coated and observed with a 
scanning electron microscope (EVO LS10, Carl Zeiss Ltd, Nanterre, France) equipped with a five 
quadrant semi-conductor backscattered electron detector. The microscope was operated at 20 keV with 
a probe current of 250 pA and a working distance of 15 mm. The backscattered raw signal was calibrated 
using pure carbon (Z=6, mean grey level = 25), pure aluminium (Z=13, mean grey level =225) and pure 
silicon (Z=14, mean grey level =253) standards (Micro-analysis Consultants Ltd, St Ives, UK). With this 
calibration, the mean grey level of pMMA resin was of 26 and the mean grey level of osteoid tissue or 
bone marrow was of 27. The cortical bone area was imaged at a 200X nominal magnification, 
corresponding to a pixel size of 0.5 µm. Two variables were obtained from the bone mineral density 
distribution of the full cortical shell: Camean as the average calcium concentration and Cawidth as the width 
of the histogram at half maximum of the peak and representing calcium heterogeneity.  
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Furthermore, we also examined the periosteal and endosteal surfaces at a 400X nominal magnification, 
corresponding to a pixel size of 0.25 µm. Then, pMMA blocks were incubated with solid elemental iodine 
(~50 mg) for 48 hours in sealed glass jar. This staining, that allows visualization of osteoid seam in 
backscattered electron mode, was first proposed by Boyde and colleagues [33]. PMMA blocks were 
further re-examined in the SEM microscope in backscattered electron mode and periosteal and 
endosteal surfaces were again recorded at a X400 nominal magnification. Images of endosteal and 
periosteal surfaces before and after iodine staining were registered and bone packets adjacent to 
osteoid seam identified. On images recorded before iodine staining, a line (3 pixel width) was drawn 
perpendicular to the osteoid seam and extended in the mineralized bone matrix using ImageJ 1.51s. 
The mean grey level of each pixel of this line was computed and plotted against the distance from the 
mineralization front. Biphasic profile were obtained at every locations. As the mineralization process of 
bone is biphasic, slopes of primary and secondary mineralization as well as the Ca turn value, 
representing the calcium concentration where the primary mineralization process changes to secondary 
mineralization process, were computed.  
 
2.7 Biochemical analyses 
For the determination of mineral composition, left tibias and femurs (n=4/group) were flushed of bone 
marrow, left to dry overnight at 60°C and weighted on a precision scale (Scaltex, SBC 32, 0.1 mg 
accuracy). Dry samples were ashed in a muffle furnace (Vecstar Furnace 91e, Eurotherm controls, 
Nantes, France) at 650°C for 18 hours and ashes were weighted on a precision scale as above. Ash 
weight was expressed as percentage of dry bone. Ashes were crushed in a fine powder, dissolved in 
0.5 M HCl and calcium and phosphate concentrations were determined with an automated 
spectrophotometer as described elsewhere [34].   
Left tibias and femurs (n=4/group) were powdered and demineralized with 0.5M EDTA in 0.05M Tris 
buffer saline for 48 hours at 4°C, reduced with 1% NaBH4 at 37°C for 1 hour and hydrolyzed in 6N HCl 
at 110°C for 24 hours in a sealed glass tube. Cross-links were separated by high-performance liquid 
chromatography. Dihydrolysinonorleucine (DHLNL) was identified and detected by post-column 
derivatization using O-phthaldehyde whilst pyridinoline (Pyr) and pentosidine (Pen) were detected by 
natural fluorescence with excitation at 295 nm and 335 nm and emission at 395 nm and 385 nm, 
respectively. Hydroxyproline content was measured by HPLC using the hydroxyproline by HPLC Bio-
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Rad kit. Collagen content was estimated from the hydroxyproline content assuming that collagen 
weighted 7.5 times the measured hydroxyproline weight, with a molecular weight of 300,000. The 
resulting data were used to calculate the cross-link content as moles per mole of collagen.  
 
2.8. Statistical analysis 
Due to the adaptive nature of bone, data were adjusted for body mass using a linear regression method 
as reported in detail elsewhere [35]. One-way analyses of variance with Tukey multiple comparison test 
were employed to test for significance between lean+saline, HFD+saline and HFD+sitaglitpin animals 
at the exception of ash weight, calcium and phosphate content and collagen cross-link concentrations, 
where a non-parametrical Kruskal-Wallis test with Dunn’s multiple comparisons were performed. 
Stepwise multiple linear regressions using the equation:  
Bone stiffness = f(β0 + β1.HOMA-IR + β2.Tt.Ar + β3.Ct.Th + β4.collagen maturity + β5.mineral maturity + 
β6.mineral/matrix ratio + β7.carbonate/phosphate ratio) 
were computerized to evaluate how bone stiffness is influenced by insulin resistance, cortical bone 
microarchitecture and composition. Differences at p equal to or less than 0.05 were considered 
significant.   
 
3. RESULTS 
 
3.1. Sitagliptin ameliorates metabolic parameters but not bone mineral densities 
As presented in Table 1, high fat diet resulted in higher body and fat masses by 24% (p=0.003) and 
37% (p=0.001), respectively. Although food intakes were similar, the higher energy content of high fat 
chow led to a significant increase in energy intake by 93% (p=0.001). Glucose tolerance and insulin 
sensitivity were also significantly impaired in HFD+saline animals as compared with lean+saline. 
Administration of sitagliptin in high fat fed animals resulted in higher non-fasting insulin level (55%, 
p=0.045), and improved glucose tolerance (32%, p=0.043), insulin sensitivity (30%, p=0.048), HOMA-
IR (24%, p=0.009) and HOMA-β (42%, p=0.030) indexes.  
However, bone mineral density assessed at either the whole body, or lumbar and femur sites, revealed 
no significant differences between the three groups of animals.  
 
3.2. Sitagliptin ameliorates whole bone stiffness and tissue bone strength 
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Next, we thought to determine whether high fat diet resulted in lower bone strength. Indeed, we observed 
that as compared with lean+saline animals, HFD+saline mice presented with lower ultimate load (-28%, 
p=0.002), stiffness (-33%, p=0.001), post-yield displacement (-45%, p=0.021) and work-to-fracture (-
35%, p=0.019) (Table 2). Administration of sitagliptin significantly augmented bone stiffness by 15% 
(p=0.019). Tissue level mechanical properties were estimated from whole-bone mechanical tests using 
equations from engineering beam theory. As compared with saline animals, HFD+saline mice presented 
with lower ultimate stress (-43%, p<0.001), yield stress (-38%, p<0.001) and elastic modulus (-48%, 
p<0.001). Administration of sitagliptin resulted in significant higher values of ultimate stress (24%, 
p=0.021), yield stress (20%, p=0.021) and elastic modulus (30%, p=0.041). Tissue level mechanical 
properties were also determined by nanoindentation. HFD resulted in lower maximum force (-22%, 
p=0.001), indentation modulus (-21%, p<0.001), indentation hardness (-27%, p=0.003) and work of 
indentation (-23%, p<0.001). Administration of sitagliptin increased indentation modulus by 12 % 
(p=0.041) in HFD animals (Table 2). Sitagliptin increased almost significantly indentation hardness 
(p=0.079) in HFD animals.  
 
3.3. Sitagliptin has no effects on trabecular and cortical microarchitectures, but augments 
osteoid surfaces and the numbers of osteoblasts and marrow adipocytes 
As bone strength at the organ level depends on bone structural and bone compositional properties, we 
next investigated cortical and trabecular bone microarchitectures (Table 3). As compared with 
lean+saline animals, HFD+saline mice presented with lower cross-sectional area, cortical area, cortical 
thickness, cortical bone density, trabecular bone volume and trabecular numbers. Administration of 
sitagliptin did not modify neither cortical nor trabecular bone microarchitectures.  
Histomorphometrical analysis of proximal tibia metaphysis revealed significant decreases in osteoid 
perimeter in HFD animals. However, administration of sitagliptin significantly increased osteoid 
perimeter by 92% as compared with HFD+saline animals. No differences in osteoid thickness were 
encountered between the three groups of animals. At the cellular level, HFD led to significant 
augmentations in the number of osteoclasts and adipocytes whilst the number of osteoblasts is reduced 
(Table 3). After sitagliptin administration, the number of osteoclasts was significantly lower (-48%, 
p=0.001) whilst osteoblast and adipocyte numbers were significantly higher (32%, p=0.001 and 77%, 
p<0.001, respectively).  
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3.4. Sitagliptin modifies bone compositional parameters in HFD mice 
As bone composition is suspected to be altered in T2DM, we first investigated how high fat diet may 
influence bone composition. Tissue mineral density within the cortical bone matrix was examined first. 
As represented in Figure 1A and supported by the bone mineral density distribution curves, HFD+saline 
animals exhibit a trend to lower calcium value. Indeed, the mean calcium concentration, Camean, was 
significantly reduced by 21% (p<0.001) without alterations of the calcium distribution heterogeneity, 
Cawidth. To assess whether mineralization kinetic was altered, we analyzed bone mineralization profile 
at site of new bone formation in cortical bone (Figure 1B). Mineralization of osteoid tissue is a biphasic 
process characterized by a rapid primary mineralization followed by slower secondary mineralization. 
The calcium concentration at which primary mineralization is replaced by secondary mineralization, 
Caturn, was significantly reduced by 19% (p<0.001) in HFD+saline animals as compared with lean+saline 
mice and supported by lower primary mineralization slope (-14%, p<0.001) rather than change in 
secondary mineralization slope. Administration of sitagliptin in HFD animals led to slight but significant 
higher Camean (5%, p=0.009), Caturn (10%, p=0.042) and slope of primary mineralization (8%, p=0.038).  
To further investigate compositional changes in the bone matrix, we examined thin bone sections by 
Fourier transform infrared imaging (FTIRI). Figure 2A represents FTIRI images over the cortical width 
of the lean+saline, HFD+saline and HFD+sitagliptin groups. Some differences in the pixel intensity 
distribution in the bone matrix were noted, especially for the mineral/matrix (M/M) ratio, mineral maturity 
(XST) and mineral crystal size index (CSI). Indeed, as compared with lean+saline animals, HFD+saline 
mice presented with significant lower collagen maturity (-23%, p<0.001), mineral maturity (-20%, 
p<0.001), crystal size index (-18%, p<0.001), mineral/matrix ratio (-27%, p<0.001) and 
carbonate/phosphate ratio (-19%, p=0.01). Administration of sitagliptin to HFD mice led to significant 
augmentations in collagen maturity by 12 % (p=0.048), mineral maturity by 4 % (p<0.001), crystal size 
index by 4% (p<0.001) and mineral/matrix ratio by 16% (p=0.045) (Figure 2B). In addition, 
heterogeneities of all the bone mineral or collagen parameters measured by FTIRI were not significantly 
different between the three groups of animals.  
Next, bone mineral content and collagen cross-link profiles were determined chemically (Table 4). Ash 
weight, calcium and phosphate content were significantly lower in HFD+saline animals as compared 
with lean+saline. Furthermore, a more pronounced reduction in enzymatic mature (Pyr) vs. immature 
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(DHLNL) collagen cross-links was observed in these animals. Non-enzymatic collagen cross-link, 
indicative of advanced glycation endproducts represented by the pentosidine content, was significantly 
and dramatically augmented in HFD+saline animals. Administration of sitagliptin led to significant higher 
values of calcium and non-significant higher phosphate (p=0.078). Mature and immature enzymatic 
collagen cross-links were also significantly augmented whilst the pentosidine content was significantly 
lowered.   
 
3.5. Changes in bone compositional parameters, cortical bone microarchitecture and insulin 
resistance are strong predictors of bone stiffness 
In order to better understand which of the above changes in cortical bone microarchitecture, bone 
composition and insulin resistance were directly linked to modifications of bone stiffness, we performed 
multiple linear regression analysis (Table 5). Data were dichotomized by groups. When only lean+saline 
and HFD+saline animals were considered, the multiple regression model exhibited an adjusted R2 value 
of 0.786, indicating that more than 78% variation in bone stiffness could be explain by changes in 
mineral/matrix ratio, cross-sectional tissue area and HOMA-IR. When HFD+saline and HFD+sitagliptin 
animals were considered, the multiple regression model exhibited an adjusted R² value of 0.696 
suggesting that the model fitted strongly with the experimental data. Predictors were mineral/matrix ratio, 
collagen maturity and HOMA-IR.  
 
4. DISCUSSION 
Type 2 diabetes mellitus progress worldwide and has been recognized as a risk factor for bone frailty. 
Among the glucose-lowering agents approved for the treatment of T2DM, some of them have been 
associated with detrimental actions on bone itself. As such, it is of utmost importance to assess the 
possible actions of glucose-lowering agents on bone physiology. Although sitagliptin was the first DPP4i 
approved in 2006, little is known about its effects on bone composition. Previous reports highlighted 
positive effects in resisting bone fracture, despite the absence or only modest ameliorations in bone 
mineral densities and/or bone microarchitectures [19, 22, 23, 36].  Taken together, these results 
suggested that the mechanisms behind better bone strength rely beyond changes in the quantity of 
bone or its structural properties.  
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Although T2DM is multifactorial, the high fat-fed swiss mice employed in the present study, presented 
with elevated fasted blood glucose level above 14 mmol/l and insulin resistance making this model a 
clear type 2 diabetic animal model. In these mice, bone strength was reduced by a combination of 
structural (Tt.Ar, Ct.Ar, Ct.Ar/Tt.Ar, Ct.Th) and compositional (collagen maturity, collagen cross-links 
profile, pentosidine content, mineral/matrix ratio, mineral crystallinity, crystal size, carbonate/phosphate 
ratio) alterations as well as insulin resistance. Bone strength was assessed by 3-point bending, which 
is a simple and reproducible test to estimate bone strength. However, the relevance of such 
biomechanical test to the mechanisms of fragility fracture in humans is questionable.  
Human data on modification of bone composition at the tissue level in diabetes mellitus are scarce and 
limited to mechanical effects at the microscale. Rodent model of diabetes mellitus have previously 
revealed alterations of bone matrix composition. In type 1 diabetes mellitus, although alteration of the 
mineral component of the bone matrix vary between animal models, clear alterations of the collagen 
moiety were evident with a reduction in enzymatic collagen cross-links and an elevation in non-
enzymatic collagen cross-linking [37-39]. In T2DM, Hammond et al. investigated the bone composition 
in the Zucker diabetic Sprague-Dawley rat, a model of spontaneous T2DM [40]. This study highlighted 
that the degree of mineralization of the bone matrix, assessed by ash fraction and bone mineral density, 
was significantly lower in diabetic animals despite no modifications of the mineral composition, i.e. 
mineral crystallinity and carbonate substitution. However, alterations of collagen fibers with higher D-
spacing were evident. This study also highlighted that the site of investigation (periosteal surfaces vs. 
whole bone) and the choice of the method of investigation (vibrational vs. physical method) could result 
in conflicting data. Indeed, the authors concluded that accumulation of advanced glycation endproducts 
in the collagen matrix may result in modification of the Raman signature of the collagen structure and 
hence a biased mineral/matrix ratio. In the present study, we used a combination of Fourier transform 
infrared spectroscopy and electron microscopy over the full cortical width, and performed biochemical 
analyses of whole bone. All these data pointed out to a lower degree of mineralization of the bone matrix, 
alterations of crystal size, lower enzymatic collagen cross-linking and higher accumulation of advanced 
glycation endproducts.  Multiple regression analyses suggested that lower mineral/matrix ratio and 
cross-sectional area were strong predictors of bone stiffness whilst insulin resistance, although 
associated with lower bone stiffness, was less important. Nevertheless, the indirect consequences of 
insulin resistance on bone cells and hence deposition/modification of bone matrix cannot be neglected.  
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The present results support also that short-term treatment with sitagliptin was sufficient to increase bone 
stiffness in HFD mice. The mechanism relied on modification of bone compositional properties rather 
than action on structural parameters. Multiple regression analyses highlighted here again the strong 
influence of mineral/matrix ratio, and hence the degree of mineralization of the bone matrix, collagen 
maturity and to a lower extent insulin resistance.  
To note is the higher number of osteoblasts and adipocytes found at the surface of bone and in the bone 
marrow, respectively. A recent elegant study from Ambrosi et al., demonstrated that DPP4 is expressed 
by adipogenic progenitor cells that block the differentiation of osteogenic progenitor cells [41]. As such, 
a plausible scenario to explain the higher osteoblast numbers and possibly the positive effects on bone 
composition may reside in the direct blockade of adipocyte-derived DPP4. This hypothesis would need 
to be demonstrated in the future but also to be verified in human tissues. Furthermore, some recent 
investigations conducted in diabetic and osteoporotic rodents (10-300 mg/kg/day sitagliptin), as well as 
in human postmenopausal diabetic women, suggest a reduction in bone resorption with sitagliptin [22, 
36, 42] supporting the lower number of osteoclasts observed in the present study.  
Another plausible scenario is represented by changes in the deposition of non-collagenous protein 
involved in the regulation of bone mineralization that could change the mineralization kinetic. This idea 
is further supported by the greater values of primary mineralization slope and Caturn, observed in the 
present study, and could indicate changes in the control of mineral deposition in the bone matrix. Greater 
mineralization degree in addition to higher mineral crystallinity and crystal size may also be interpreted 
by modifications in the control of mineral deposition in bone.  
A limitation to this study is the lack of double administration of fluorochrome. We could not measure 
dynamic histomorphometrical indexes and we could not measure precisely by Fourier transform infrared 
microspectroscopy the effects of sitagliptin administration at bone forming site.  
Another limitation is represented by the fact that the present study was conducted in a rodent model of 
type 2 diabetes mellitus and not in humans. Bone biopsies of human individuals suffering of type 2 
diabetes mellitus are rare worldwide. The amount of specimen is even lower if only DPP4i-treated 
patients are considered. As such, due to species differences at all levels, it is difficult to guarantee that 
the observed beneficial role of sitagliptin in our rodent model may be extrapolated to humans.   
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
15 
 
In conclusion, the present study provides new insight in to the mode of action of sitagliptin on bone in 
diabetes. Indeed, sitagliptin ameliorated bone biomechanical properties by positively modifying bone 
composition rather than affecting bone microstructure. Further studies are required to ascertain whether 
such effects occur in humans, but the results of this study are highly encouraging to the goal of improving 
bone strength in type-2 diabetes and aiding clinicians regarding selection of anti-diabetic drugs in 
patients at high risk of bone fractures.   
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7. FIGURE LEGENDS 
Figure 1 [On-line color only]: Effects of high fat diet and sitagliptin on tissue mineral distribution. 
Bone mineral density distribution was evaluated by qBEI in lean+saline, HFD+saline and 
HFD+sitagliptin. (A) Representative calcium maps with their respective calcium distribution. Camean 
represents the mean degree of mineralization and Cawidth represents the heterogeneity in the degree of 
mineralization. Values are means ± SEM for 8 mice. **: p<0.01 and ***: p<0.001 vs. HFD+saline.  ###: 
p<0.001 vs. lean+saline. (B) Bone mineralization profile. The slopes of primary and secondary 
mineralization have been computerized as well as Caturn that represents the calcium concentration at 
which primary mineralization is followed by secondary mineralization. Values are means ± SEM for 8 
mice. *: p<0.05 and ***: p<0.001 vs. HFD+saline. #: p<0.05 vs. lean+saline.  
Figure 2 [On-line color only]: Effects of high fat diet and sitagliptin on compositional parameters 
of the bone matrix. Bone composition parameters were also assessed by Fourier transform infrared 
imaging (FTIRI). (A) Some FTIRI images are presented. The pseudo-color represents the degree of 
each parameter overall the full width of the cortical bone. CCL: collagen maturity, XST: mineral maturity, 
CSI: crystal size index, M/M: mineral/matrix ratio, C/P: carbonate/phosphate ratio and AcP: acid 
phosphate content. (B) The mean and heterogeneity of each parameter was also investigated and 
represented next to FTIRI images. Values are means ± SEM for 8 mice. *: p<0.05, **: p<0.01 and ***: 
p<0.001 vs. HFD+saline. #: p<0.05, ##: p<0.01 and ###: p<0.001 vs. lean+saline.   
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8. TABLES 
Table 1: Metabolic parameters after 3 weeks administration of saline or sitagliptin 
 Lean+saline HFD+saline HFD+sitagliptin 
Body mass (g) 45 ± 2aa 56 ± 1 54 ± 1bb 
Fat mass (%) 25 ± 1aa 34 ± 1 32 ± 1b 
Food intake (g/day) (kj/day) 4.2 ± 0.3 4.1 ± 0.5 3.9 ± 0.7 
Energy intake (kj/day) 55 ± 4aa 106 ± 12 102 ± 16b 
Non-fasting insulin (ng/ml) 1.7 ± 0.6 2.0 ± 0.4 3.1 ± 0.3a 
AUC0-60min Glucose tolerance (mmol/l.min) 417 ± 32aaa 614 ± 40 418 ± 74a 
AUC0-60min insulin sensitivity (ng/ml.min) 97 ± 11a 58 ± 10 139 ± 36a 
HOMA-IR 5.4 ± 0.5 6.6 ± 0.5 4.4 ± 0.5aa 
HOMA- 604 ± 89 276 ± 265 1048 ± 176a,b 
Whole body BMD (mg/cm²) 61 ± 1 64 ± 1 64 ± 1 
Lumbar BMD (mg/cm²) 60 ± 1 68 ± 1 66 ± 4 
Femur BMD (mg/cm²) 105 ± 4 111 ± 2 116 ± 3 
Values are means ± SEM for 8 mice. a: p<0.05, aa: p<0.01 and aaa: p<0.001 vs. HFD+saline. b: p<0.05, 
bb: p<0.01 and bbb: p<0.001 vs. Lean+saline.  
 
Table 2: Whole-bone and tissue-level mechanical properties 
 Lean+saline HFD+saline HFD+sitagliptin 
Whole-bone level 
Maximum load (N) 32 ± 2aa 23 ± 1 24 ± 1 
Stiffness (N/mm) 159 ± 11aa 106 ± 4 123 ± 4a 
Postyield displacement (mm) 0.28 ± 0.03a 0.16 ± 0.02 0.26 ± 0.06 
Work-to-fracture (N.mm) 9.3 ± 0.8a 6.1 ± 0.5 7.8 ± 0.8 
Tissue level (3-point bending) 
Ultimate stress (MPa) 237 ± 12aaa 136 ± 4 168 ± 4a, bbb 
Yield stress (MPa) 192 ± 8aaa 120 ± 3 143 ± 5a, bbb 
Elastic modulus (GPa) 11.1 ± 1.0aaa 5.7 ± 0.3 7.4 ± 0.1a, bb 
Tissue level (Nanoindentation) 
Maximum force (mN) 14.3 ± 0.7aa 11.2 ± 0.2 11.7 ± 0.4bb 
Indentation modulus (GPa) 15.7 ± 0.6aa 12.3 ± 0.5 13.8 ± 0.3a,bb 
Indentation hardness (MPa) 786 ± 51aa 577 ± 23 690 ± 26 
Work of indentation (pJ) 3488 ± 116aaa 2688 ± 91 2929 ± 72bb 
Values are means ± SEM for 8 mice. a: p<0.05, aa: p<0.01 and aaa: p<0.001 vs. HFD+saline. b: p<0.05, 
bb: p<0.01 and bbb: p<0.001 vs. lean+saline. 
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Table 3: Microarchitectural and histomorphometrical properties of cortical and trabecular bone 
after saline or sitagliptin administration in high fat fed mice 
 Lean+saline HFD+saline HFD+sitagliptin 
Cortical bone 
Tt.Ar (mm2) 2.2 ± 0.1a 1.9 ± 0.1 2.0 ± 0.1 
Ma.Ar (mm2) 0.8 ± 0.0 0.7 ± 0.1 0.9 ± 0.1 
Ct.Ar (mm2) 1.4 ± 0.0aaa 1.1 ± 0.0 1.2 ± 0.0bbb 
Ct.Ar/Tt.Ar (%) 74 ± 1aaa 57 ± 2 55 ± 2bbb 
Ct.Th (µm) 246 ± 5aaa 191 ± 5 191 ± 6bbb 
Trabecular bone 
BV/TV (%) 21.0 ± 0.7aaa 11.8 ± 0.8 10.8 ± 1.1bbb 
Tb.N (1/mm) 3.1 ± 0.1aaa 1.5 ± 0.2 1.5 ± 0.2bbb 
Tb.Th (µm) 77 ± 2 76 ± 5 67 ± 3 
Tb.Sp (µm) 260 ± 9 295 ± 25 299 ± 20 
OS/BS (%) 4.1 ± 0.5aaa 1.4 ± 0.3 2.7 ± 0.4aa,bb 
O.Th (µm) 2.3 ± 0.5 3.4 ± 1.0 3.3 ±1.0 
N.Ob/B.Pm (1/mm) 2.5 ± 0.1aa 1.8 ± 0.1 3.3 ± 0.4aa,b 
N.Oc/B.Pm (1/mm) 0.6 ± 0.1aa 1.2 ± 0.2 0.6 ± 0.1aa 
N.Ad/Ma.Ar (1/mm2) 20 ± 1aa 35 ± 2 61 ± 5aaa,bbb 
Values are means ± SEM for 8 mice. a: p<0.05, aa: p<0.01 and aaa: p<0.001 vs. HFD+saline. bbb: p<0.001 
vs. Lean+saline. 
 
Table 4: Bone mineral content and collagen cross-link profiles 
 Lean+saline HFD+saline HFD+sitagliptin 
Ash weight (%) 59.5 ± 1.2aa 52.0 ± 0.4 55.4 ± 0.6 
Calcium (mg/g ash) 362 ± 2aa 339 ± 1 351 ± 1a 
Phosphate (mg/g ash) 194 ± 1aa 184 ± 1 190 ± 1 
Pyr (mmol/mol collagen) 238 ± 18aa 160 ± 9 193 ± 9a 
DHLNL (mmol/mol collagen) 668 ± 24aa 520 ± 14 583 ± 13a 
Pentosidine (mmol/mol collagen) 75 ± 10aaa 270 ± 16 198 ± 11a 
Values are means ± SEM for 4 mice/group. a: p<0.05, aa: p<0.01 and aaa: p<0.001 vs. HFD+saline. bbb: 
p<0.001 vs. Lean+saline 
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Table 5: Multiple regression analyses of the relation between mechanical properties (Stiffness), 
insulin resistance, cortical bone microarchitecture and bone compositional parameters.  
Dependent 
variable 
Groups Model 
adjusted 
R² 
Model 
p value 
Parameter β Parameter 
p value 
Stiffness 
Lean+saline vs 
HFD+saline 
0.786 <0.001 
Intercept -104.873 0.023 
Mineral/matrix 
ratio 
48.144 <0.001 
Tt.Ar 36.261 0.050 
HOMA-IR -8.379 0.024 
HFD+saline vs 
HFD+sitagliptin 
0.696 <0.001 
Intercept -65.014 0.029 
Mineral/matrix 
ratio 
43.142 <0.001 
Collagen maturity 18.770 0.004 
HOMA-IR -6.267 <0.001 
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